🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

BioLife Solutions, Inc. BLFS R2K

Healthcare · Medical Instruments & Supplies · United States
https://www.biolifesolutions.com
Company Profile ↓
$28.65
+30.11% 1Y
Mkt Cap$1.40B
P/E-119.38
P/B3.42
52W High$28.79
52W Low$18.15
Book Value$7.62
EPS (TTM)$-0.24

Company Overview

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 31.5% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $96.21M (+28.9% YoY); net profit $-4.59M.
  • Trailing 12 Months Year-on-year growth — revenue +24.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 31.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:31.50%
1 Year:24.70%

Stock Price Performance

1 Year:+30.11%
6 Months:+15.25%
3 Months:+42.47%
1 Month:+7.71%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 99% of range
$18.15 $28.79
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)62.03 · Neutral
Price Performance
1M+7.71%
3M+42.47%
6M+15.25%
1Y+30.11%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 31.5% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-119.38
Industry PE
25.41
Forward P/E
98.79
PEG Ratio
15.09
Book Value
$7.62
Price to Book
3.42
P/S
12.54
EV/EBITDA
279.81
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
31.50%
Profit 5Y
-
Revenue (YoY)
24.70%
Earnings (YoY)
-

Profitability & Returns

ROCE
-4.34%
ROE
-3.09%
ROA
-0.09%
Profit Margin
-2.91%
Op Margin
0.10%
Gross Margin
63.76%
EPS (Latest Qtr)
$0.02
EPS (TTM)
$-0.24

Balance Sheet & Liquidity

Debt/Equity
3.99
Quick Ratio
5.15
Current Ratio
7.30
Debt
$14.86M
Total Assets
$400.91M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
2.37%
Chg in Prom Hold
-0.01%
FII / Inst Holding
104.49%
Chg in FII Hold
-0.02%

Financial Snapshot

Enterprise Value
$1.40B
Total Revenue (TTM)
$101.66M
EBITDA
$4.32M
Free Cash Flow
$6.39M
Operating Cash Flow
$17.90M
Shares Outstanding
48.86M
Gross Margin
63.76%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BLFS BioLife Solutions, Inc. R2K 28.65 -119.38 $1.40B 0.00% -4.34% -3.09% 31.50% -
2 LLY Eli Lilly and Company SPX 1,152.54 41.02 $1.03T 0.61% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 253.85 29.45 $611.07B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.78 119.40 $432.48B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 425.19 32.02 $386.13B 2.27% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 120.78 34.02 $298.31B 2.86% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 164.50 24.81 $255.12B 1.77% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 534.07 29.33 $198.47B 0.40% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 355.25 24.69 $191.73B 2.84% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2013Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue 2.16M2.33M2.17M2.07M1.21M1.24M----------------------------------
Gross Profit 1.13M828.44K888.86K903.39K545.32K588.39K882.62K818.65K973.38K1.08M1.12M1.21M1.44M1.60M1.87M2.45M3.64M3.69M4.12M4.74M4.52M---------------14.80M--17.50M
Operating Income 192.33K-82.84K-110.09K-369.04K-887.87K-874.51K-1.16M-1.16M-1.30M-1.49M-1.59M-1.14M-464.04K-341.20K-32.34K140.00K1.28M1.20M566.00K747.00K-772.00K370.00K44.00K-1.25M-981.00K-4.55M-11.16M-7.97M-76.56M-11.74M-13.61M-10.63M-15.47M-3.29M-1.31M-418.00K-499.00K-16.64M-89.00K27.00K
Net Income -7.18K-282.51K-309.91K-559.37K-883.36K-862.46K-1.03M-994.38K-1.07M-1.23M-1.36M-969.00K-870.29K-768.21K-318.72K4.87M-26.35M-24.46M-19.16M4.25M10.27M22.31M-16.38M-1.13M-1.12M7.88M79.00K-7.42M-72.88M-10.32M-13.71M-10.20M-29.13M-10.22M-20.72M-1.70M-448.00K-15.84M621.00K1.19M
Diluted EPS --------------0.06-0.03-0.02-1.74-1.42-1.030.020.35-0.01-0.70-0.04-0.030.190.00--1.72-0.24-0.32-0.23-0.67-0.22-0.45-0.040.00-0.330.010.02
R&D Expense 105.97K94.91K160.53K167.29K192.78K153.33K322.17K301.33K329.53K504.24K599.03K496.87K286.75K318.61K293.09K346.00K325.00K312.00K359.00K691.00K1.03M1.66M1.48M1.73M1.99M3.04M3.22M3.78M3.43M3.42M4.15M3.79M3.74M2.08M2.03M1.89M1.44M2.72M2.71M2.65M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 2.08M2.76M5.66M8.95M6.19M6.45M8.23M11.02M19.74M27.37M48.09M-76.24M68.02M74.65M96.21M
Cost of Revenue ------------29.33M26.70M24.55M34.10M
Gross Profit 856.39K1.40M2.29M3.76M3.04M3.81M4.78M6.75M13.53M---46.91M41.32M50.10M62.12M
Operating Expenses ------------57.59M60.72M54.57M78.72M
Operating Income -1.39M-1.21M-942.24K-285.36K-3.14M-5.02M-4.85M-1.06M3.66M-220.00K-6.24M--10.68M-19.40M-4.48M-16.60M
EBITDA ------------5.79M-7.10M4.18M-11.91M
Interest Expense ----------------
Pretax Income -------------4.85M-12.22M-8.82M-12.08M
Tax Provision -------------5.24M-64.00K-38.00K49.00K
Net Income -1.98M-1.96M-1.66M-1.08M-3.22M-4.21M-6.88M-2.52M-25.00M-1.66M1.98M--139.81M-68.00M-20.18M-4.59M
Diluted EPS --------0.21-1.56-0.09-0.06--3.29-1.55-0.44-0.10
R&D Expense 318.90K516.45K463.64K487.82K871.10K1.38M2.03M1.19M1.30M3.17M6.72M11.82M8.67M5.51M4.75M7.57M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Jan 2018Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -1.31M1.66M3.17M3.35M16.07M12.37M7.93M12.14M-12.29M21.79M46.45M45.47M48.07M51.30M83.79M92.82M234.83M554.29M450.23M412.71M399.49M405.88M
Total Equity -7.83M-9.55M-11.18M-12.49M-13.27M13.94M8.51M3.17M-9.53M-9.53M-4.25M-12.94M-6.50M14.63M-3.74M2.07M35.19M43.32M204.43M478.05M364.19M337.66M348.91M371.89M
Cash & Equivalents 139.15K3.21K16.86K196.48K156.27K2.54M2.17M1.41M6.66M-7.03M14.17M32.38M30.66M31.82M19.62M21.20M6.45M90.40M69.86M19.44M27.90M91.54M33.04M
Long Term Debt -------4.25M---------13.00K655.00K6.35M23.79M17.56M5.00M0
Total Liabilities -10.86M12.84M15.66M16.62M2.14M2.51M4.76M2.05M-16.55M34.73M52.94M30.84M51.81M49.23M48.60M49.36M29.58M76.24M86.04M75.05M50.58M34.00M
Current Liabilities -340.70K579.25K1.37M1.63M1.26M1.73M1.13M1.51M-1.31M1.66M2.10M1.94M2.70M3.16M5.01M7.67M15.57M42.70M44.58M42.18M32.73M22.98M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -1.25M-989.92K854.93K146.01K-3.16M-4.97M-4.33M605.00K2.35M1.21M6.64M-4.59M-8.49M-12.50M8.43M20.11M
Investing Cash Flow -28.41K-91.43K-1.15M-236.67K-8.14M4.24M392.79K-144.00K-6.50M-27.02M-24.71M-13.19M-58.12M17.84M58.30M-71.54M
Financing Cash Flow 1.15M1.09M475.00K50.46K13.68M368.75K3.17M4.80M28.15M1.60M102.08M-2.78M16.32M10.59M-6.78M-10.92M
Capital Expenditure -28.41K-93.53K-1.15M-236.67K-589.68K-134.01K-143.53K-144.00K-500.00K-675.00K-1.96M-8.38M-10.38M-6.38M-3.23M-9.48M
Free Cash Flow -1.28M-1.08M-296.79K-90.66K-3.75M-5.11M-4.47M461.00K1.85M538.00K4.68M-12.98M-18.87M-18.88M5.20M10.64M

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 41.1%50.9%40.5%42.0%49.0%59.1%58.1%61.2%68.5%---61.5%60.7%67.1%64.6%
Operating Margin % -67.0%-43.8%-16.6%-3.2%-50.7%-77.8%-59.0%-9.6%18.5%-0.8%-13.0%--14.0%-28.5%-6.0%-17.3%
Net Margin % -95.3%-70.9%-29.3%-12.1%-52.0%-65.3%-83.6%-22.8%-126.7%-6.1%4.1%--183.4%-100.0%-27.0%-4.8%
ROE % 20.8%17.5%13.3%8.2%-23.1%-49.5%-217.1%26.4%-170.9%-3.8%1.0%--38.4%-20.1%-5.8%-1.2%
ROCE % -144.0%-111.7%-52.2%-16.5%-21.2%-47.1%-71.4%-9.9%8.4%-0.3%-2.8%--2.6%-5.2%-1.2%-4.3%

Shareholding Pattern

Insiders
2.37%
Institutions
104.49%
Public Float
107.03%

Top Institutional Holders

#Holder% HeldSharesValue
1 T. Rowe Price Investment Management, Inc. 13.32% 6.51M $181.43M
2 Blackrock Inc. 12.49% 6.10M $170.15M
3 Casdin Capital, LLC 12.19% 5.96M $166.12M
4 Invesco Ltd. 4.81% 2.35M $65.49M
5 Vanguard Capital Management LLC 3.93% 1.92M $53.48M
6 State Street Corporation 3.23% 1.58M $43.98M
7 FMR, LLC 3.01% 1.47M $41.00M
8 Massachusetts Financial Services Co. 2.45% 1.20M $33.39M
9 Fred Alger Management, LLC 2.21% 1.08M $30.11M
10 Dimensional Fund Advisors LP 2.12% 1.04M $28.88M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BLFS

Yahoo Finance hu, 18 Jun 2026

What Makes BioLife Solutions (BLFS) a Compelling Long-Term Hold?

Prosper Stars & Stripes, a long/short equity fund, recently released its first-quarter 2026 investor letter. A copy of the letter is available to download here. In Q1 2026, the portfolio underperformed with a net return of (-5.6%) compared …

Yahoo Finance hu, 04 Jun 2026

BioLife Solutions Leads 3 Stocks Estimated To Be Trading Below Fair Value

The United States market remained flat over the last week but has seen a 26% increase over the past year, with earnings forecast to grow by 17% annually. In such a market environment, identifying stocks that are trading below their fair val…

Yahoo Finance Fri, 29 May 2026

Orthofix Medical and 5 More Stocks See Action From Activist Investors

Activists also report to the SEC on BioLife Solutions, Garrett Motion, Life Time Group Holdings, Infleqtion, and CBL Properties.

Yahoo Finance Mon, 11 May 2026

A Look At BioLife Solutions (BLFS) Valuation As Shares Show Recent Short Term Momentum

Why BioLife Solutions (BLFS) is on investors’ radar BioLife Solutions (BLFS) has drawn attention after recent share price moves, with the stock up about 21% over the past month and roughly 3% in the past 3 months. For investors tracking the…

Yahoo Finance Fri, 08 May 2026

BioLife (BLFS) Q1 2026 Earnings Transcript

Good afternoon, everyone, and thank you for joining us for BioLife's First Quarter 2026 Conference Call. Performance in the quarter was driven by continued strength across our broader product portfolio, led by our biopreservation media or …

Yahoo Finance Fri, 08 May 2026

BioLife Solutions, Inc. Q1 2026 Earnings Call Summary

Moby summary of BioLife Solutions, Inc.'s Q1 2026 earnings call

BLFS — Frequently Asked Questions

What is the current share price of BioLife Solutions, Inc. (BLFS)?

As of 2026-07-14 21:23 PDT, BioLife Solutions, Inc. (BLFS) trades at $28.65 on NasdaqCM. Its 52-week range is $18.15 to $28.79.

What is the market capitalisation of BLFS?

BioLife Solutions, Inc. (BLFS) has a market capitalisation of $1.40B on NasdaqCM.

What is the P/E ratio of BLFS?

BLFS trades at a trailing price-to-earnings (P/E) ratio of -119.38. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.42.

What is the return on equity (ROE) of BLFS?

BLFS has a return on equity (ROE) of -3.09%. Its return on capital employed (ROCE) is -4.34%.

Is BLFS a good stock to buy?

This page provides a data-driven analysis of BioLife Solutions, Inc. (BLFS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space